Congress quietly shifts diagnostic test oversight from FDA to labs themselves

What it does

This bill creates a new regulatory framework for laboratory-developed tests (LDTs)—diagnostic tests designed and performed within individual clinical labs—requiring them to demonstrate analytical and clinical validity before use. Labs must register tests in a centralized database, report serious errors within 5 days, and may seek optional third-party validation (including from the FDA) to confirm their tests meet standards. The bill shifts LDT oversight from the FDA's device-regulation authority to CLIA (the Clinical Laboratory Improvement Amendments), keeping tests under lab-based regulation rather than treating them as commercial medical devices.

Why we flagged it

The bill's core mechanism is to exempt laboratory-developed tests from FDA device regulation and create a parallel CLIA-based approval pathway with optional third-party validation. This is a structural deregulation that benefits labs and diagnostic companies by reducing FDA oversight burden, framed as 'enhancing' clinical laboratory innovation.

What the text implies

• Labs can self-attest to test validity without mandatory third-party review; the 'applicable standard' is met if a lab documents its own evidence, making validation largely self-policing until HHS challenges the test.
• The centralized database is designed to be transparent to 'stakeholders' but protects trade secrets and confidential commercial information, limiting public visibility into which tests are actually in use and their performance data.

The full analysis lists 5 implications of this text.

Who stands to gain

Clinical laboratory operators (especially large, multi-lab corporate entities with common ownership); In vitro diagnostic device manufacturers (whose devices can be modified for LDT use without FDA over; Third-party validation organizations (newly created market for supplemental affirmations)